With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
|Articles|February 16, 2021
Supplements and Featured Publications
- Current and Emerging Trends in Chronic Myeloid Leukemia
- Volume 1
- Issue 1
Current and Future Trends in Chronic Myeloid Leukemia
Advertisement
This publication includes a summary of data on therapeutic agents for the current and future treatment landscape of chronic myeloid leukemia. Hematologic oncology experts provide key insights on approaching disease management, including a discussion on treatment options through later-line settings.
Articles in this issue
almost 6 years ago
Dr. Cortes on the Future of Ponatinib in CML Treatmentalmost 6 years ago
Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CMLalmost 6 years ago
Dr. Cortes on Navigating Among Frontline TKIs in the CML Paradigmalmost 6 years ago
Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CMLalmost 6 years ago
Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CMLalmost 6 years ago
Dr. Sweet on Treatment Selection With TKIs in CMLAdvertisement
Related to this article
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5